tetano
Editor, Senior Moderator
Vaccine
Available online 2 March 2012
Immune responses and protective efficacy of a recombinant swinepox virus expressing HA1 against swine H1N1 influenza virus in mice and pigs
Jiarong Xua,
Dongyan Huanga, b,
shichao Liua,
Huixing Lina,
Haodan Zhua,
Bao Liua,
Chengping Lua, Corresponding author contact information, E-mail the corresponding author
a College of Veterinary Medicine, Nanjing Agricultural University, Nanjing 210095, China
b College of Animal Science and Technology, Jiangxi Agricultural University, Nanchang 330045, China
Received 28 November 2011. Revised 27 January 2012. Accepted 10 February 2012. Available online 2 March 2012.
http://dx.doi.org/10.1016/j.vaccine.2012.02.028,
Abstract
Swine influenza virus (SIV) is not only an important respiratory pathogen in pigs but also a potent threat to human health. Although immunization with recombinant poxviruses expressing protective antigens as vaccines has been widely used for against many infectious diseases, development of recombinant swinepox virus (rSPV) vector for the purpose has been less successful. Here, we report the construction of a recombinant swinepox virus (rSPV-HA1) expressing hemagglutinin (HA1) of H1N1 SIV. Immune responses and protection efficacy of the vaccination vector were evaluated in both mouse model and natural host pig. Prime and boost inoculations of rSPV-HA1 yielded high levels of neutralization antibody against SIV and elicited potent H1N1 SIV-specific IFN-γ response from T-lymphocytes. Complete protection of pigs against H1N1 SIV challenge was observed. No pigs showed evident systemic and local reactions to the vaccine and no SIV shedding was detected from pigs vaccinated with rSPV-HA1 after challenge. Our data demonstrated that the recombinant swinepox virus encoding HA1 of SIV H1N1 may serve as a promising SIV vaccine for protection against SIV infection.
Highlights
► This is the first construction of recombinant SPV expressing HA1 of H1N1 SIV. ► The recombinant rSPV-HA1 can express HA1 of H1N1 SIV in vitro. ► rSPV-HA1 can induce specific humoral and cell-mediated immune responses in animals. ► Administration of rSPV-HA1 provides a complete protection against H1N1 SIV in pigs.
http://www.sciencedirect.com/science/article/pii/S0264410X12002113
Available online 2 March 2012
Immune responses and protective efficacy of a recombinant swinepox virus expressing HA1 against swine H1N1 influenza virus in mice and pigs
Jiarong Xua,
Dongyan Huanga, b,
shichao Liua,
Huixing Lina,
Haodan Zhua,
Bao Liua,
Chengping Lua, Corresponding author contact information, E-mail the corresponding author
a College of Veterinary Medicine, Nanjing Agricultural University, Nanjing 210095, China
b College of Animal Science and Technology, Jiangxi Agricultural University, Nanchang 330045, China
Received 28 November 2011. Revised 27 January 2012. Accepted 10 February 2012. Available online 2 March 2012.
http://dx.doi.org/10.1016/j.vaccine.2012.02.028,
Abstract
Swine influenza virus (SIV) is not only an important respiratory pathogen in pigs but also a potent threat to human health. Although immunization with recombinant poxviruses expressing protective antigens as vaccines has been widely used for against many infectious diseases, development of recombinant swinepox virus (rSPV) vector for the purpose has been less successful. Here, we report the construction of a recombinant swinepox virus (rSPV-HA1) expressing hemagglutinin (HA1) of H1N1 SIV. Immune responses and protection efficacy of the vaccination vector were evaluated in both mouse model and natural host pig. Prime and boost inoculations of rSPV-HA1 yielded high levels of neutralization antibody against SIV and elicited potent H1N1 SIV-specific IFN-γ response from T-lymphocytes. Complete protection of pigs against H1N1 SIV challenge was observed. No pigs showed evident systemic and local reactions to the vaccine and no SIV shedding was detected from pigs vaccinated with rSPV-HA1 after challenge. Our data demonstrated that the recombinant swinepox virus encoding HA1 of SIV H1N1 may serve as a promising SIV vaccine for protection against SIV infection.
Highlights
► This is the first construction of recombinant SPV expressing HA1 of H1N1 SIV. ► The recombinant rSPV-HA1 can express HA1 of H1N1 SIV in vitro. ► rSPV-HA1 can induce specific humoral and cell-mediated immune responses in animals. ► Administration of rSPV-HA1 provides a complete protection against H1N1 SIV in pigs.
http://www.sciencedirect.com/science/article/pii/S0264410X12002113